Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Finerenone on Morbidity and Mortality in Participants With Heart Failure (NYHA II-IV) and Left Ventricular Ejection Fraction ≥ 40% (LVEF ≥ 40%)

Next Previous
Trial Profile

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Finerenone on Morbidity and Mortality in Participants With Heart Failure (NYHA II-IV) and Left Ventricular Ejection Fraction ≥ 40% (LVEF ≥ 40%)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Finerenone (Primary)
  • Indications Heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms FINEARTS-HF
  • Sponsors Bayer

Most Recent Events

  • 03 Jun 2025 According to Bayer media release, data from this trial will be presented at the European Renal Association (ERA) 62nd Congress scientific sessions in Vienna, Austria, June 4-7, 2025.
  • 28 Mar 2025 According to RWJBarnabas Health and Rutgers Health media release, Physician-scientists from RWJBarnabas Health and Rutgers Health will present data highlights from this study at American College of Cardiology Annual Scientific Session & Expo (ACC.25), taking place in Chicago, IL from March 29-31, 2025.
  • 25 Mar 2025 According to Bayer media release, data from this trial will be presented at the American College of Cardiology (ACC) 74th Annual Scientific Session & Expo 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top